Anti-CD19 [BU12]
Invented at University Of Birmingham
- Datasheet
- References (9)
- Inventor Info
Info
| Catalogue Number | 151429 |
| Applications | FACS IHC IP |
| Antigen/Gene or Protein Targets | CD19 |
| Synonyms | CD19 Molecule; B-Lymphocyte Surface Antigen B4; T-Cell Surface Antigen Leu-12; Differentiation Antigen CD19; CD19 Antigen; CVID3; B4 |
| Reactivity | Human |
| Relevance | CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. It is a single chain glycoprotein, present on the surface of normal and neoplastic B-cells. CD19 is expressed at an early stage by projenitor B-cells in bone marrow and during all stages of B-cell maturation. This antigen is lost upon terminal differentiation to plasma cells. CD19 is important for detecting both normal and neoplastic B-cells. CD19 is present on neoplasms arising from early B-cells (e.g. acute leukaemia of pre-B-cells) and more differentiated B-cell neoplasms (e.g. chronic Lymphocytic leukaemia and non-Hodgkin's lymphoma). Leukaemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The CD19 cytoplasmic domain binds tyrosine kinases and PI-3 kinase. |
| Host | Mouse |
| Immunogen | Human EB-4 Burkitt's lymphoma cell line |
| Subclass | IgG1 |
| Recommended Growing Conditions | RPMI 1640 + 10% FCS |
| Strain | Balb/c |
| Notes | FACS dilution: 1/50 to 1/200 |
| Research Area | Cancer, Cell Signaling & Signal Transduction, Immunology, Stem Cell Biology |
References: 9 entries
Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
Europe PMC ID: 27338475
Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
FACS
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Europe PMC ID: 16771848
Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
Europe PMC ID: 7595190
Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.
Europe PMC ID: 1374445
Add a reference
References: 9 entries
Bortolotti et al. 2016. Toxins (Basel). 8(6):. PMID: 27338475.
High in Vitro Anti-Tumor Efficacy of Dimeric Rituximab/Saporin-S6 Immunotoxin.
Flavell et al. 2006. Br J Haematol. 134(2):157-70. PMID: 16771848.
FACS
The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Behr et al. 1995. J Exp Med. 182(5):1191-9. PMID: 7595190.
Engaging CD19 or target of an antiproliferative antibody 1 on human B lymphocytes induces binding of B cells to the interfollicular stroma of human tonsils via integrin alpha 4/beta 1 and fibronectin.
Schlossman SF. et al. 1995. Leucocyte Typing V. Oxford University Press
Callard et al. 1992. J Immunol. 148(10):2983-7. PMID: 1374445.
CD19 regulation of human B cell responses. B cell proliferation and antibody secretion are inhibited or enhanced by ligation of the CD19 surface glycoprotein depending on the stimulating signal used.
Add a reference
